<DOC>
	<DOC>NCT02330549</DOC>
	<brief_summary>A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study of CVC to be conducted in approximately 50 adult obese subjects (BMI ≥ 30 kg/m2) with prediabetes or type 2 diabetes mellitus and suspected NALFD.</brief_summary>
	<brief_title>ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD</brief_title>
	<detailed_description>Approximately 50 adult obese subjects (BMI ≥ 30 kg/m2) with prediabetes or type 2 diabetes mellitus and suspected NALFD will be randomized into the study. Eligible subjects will receive either CVC (n=25) or matching placebo (n=25), once daily (QD) for 24 weeks, followed by a safety follow-up visit 4 weeks after last intake of study medication.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>TAK-652</mesh_term>
	<criteria>Adult male and female subjects aged between 1875 years Obesity as defined by BMI ≥ 30 kg/m2 Evidence of prediabetes or type 2 diabetes mellitus based on Screening laboratory values with at least one of the following criteria: Fasting plasma glucose (FPG) of 100 270 mg/dL (5.6 15.0 mmol/L) Hemoglobin A1c (HbA1c) of 5.7 10.0% Subjects receiving metformin alone or in combination with a sulfonylurea (glimepiride, glipizide, glyburide, or gliclazide) must be on stable therapy for at least 90 days prior to Screening. Suspected diagnosis of NAFLD warranting confirmation by liver biopsy AST and ALT ≤ 5 ULN Ability to understand and sign a written informed consent form Females of childbearing potential and males participating in the study must agree to use at least 2 approved barrier methods of contraception throughout the duration of the study and for 3 months after stopping study drug. Females who are postmenopausal must have documentation of cessation of menses for ≥ 12 months and serum follicle stimulating hormone (FSH) ≥ 30 mU/mL Subjects receiving allowed concomitant medications need to be on stable therapy for 28 days prior to Baseline Use of OHAs other than metformin or sulfonylureas, including but not limited to thiazolidinediones, DPP4 inhibitors, SGLT2 inhibitors, GLP1 receptor agonists, meglitinides, αglucosidase inhibitors, colesevelam, bromocriptine, pramlintide or basal insulin within 90 days prior to Screening or anticipated use during the trial Type 1 diabetes HBsAg positive HIV1 or HIV2 infection HCVAb positive Prior or planned liver transplantation Other known causes of chronic liver disease, including alcoholic liver disease History of cirrhosis and/or hepatic decompensation including ascites, encephalopathy or variceal bleeding Alcohol consumption greater than 14 units/week Weight reduction through bariatric surgery or planned bariatric surgery during the conduct of the study (including gastric banding) Any Grade ≥ 3 laboratory abnormality as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Toxicity Grading Scale, except subjects with Grade ≥ 3 dyslipidemia with triglyceride or cholesterol elevations unless clinical assessment foresees an immediate health risk to the subject Serum albumin &lt; 3.5 g/dL Serum creatinine levels ≥ 1.5 mg/dL for males or ≥ 1.4 mg/dL for females if subject is receiving metformin Estimated glomerular filtration rate (eGFR) &lt; 50 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) equation Platelet count &lt; 100,000/mm3 Hemoglobin &lt; 12 g/dL for males or &lt; 11 g/dL for females Females who are pregnant or breastfeeding Receiving ongoing therapy with any disallowed medication at Screening Allergy to the study drug or its components Any other clinically significant disorders or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing and protocol requirements</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>